2015 Original PMAs And Panel-Track Supplements
This article was originally published in The Gray Sheet
A sortable and searchable table of FDA original PMAs and panel-track supplements approved in 2015, updated monthly. Latest update: Approvals through Nov. 30.
You may also be interested in...
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.
The FDA has almost 30 decision dates coming up before New Year’s Eve, including nearly a dozen novel agents.